A prospective, non-blinded, pilot, single-center study to evaluate whether the add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Mitiglinide (Primary) ; Insulin glargine; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 01 Feb 2016 New trial record